Baker Bros. Advisors’s Roivant Sciences ROIV Stock Holding History

Baker Bros. Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$167M	Sell	4,716,831 -150,892	-3%	-$4.46M	0.84%	19
2026 Q1	$135M	Sell	4,867,723 -687,294	-12%	-$17.7M	0.77%	19
2025 Q4	$121M	Buy	5,555,017 +1,787,244	+47%	+$35.3M	0.71%	21
2025 Q3	$57M	Hold	3,767,773	–	–	0.41%	26
2025 Q2	$42.5M	Hold	3,767,773	–	–	0.41%	28
2025 Q1	$38M	Hold	3,767,773	–	–	0.42%	27
2024 Q4	$44.6M	Buy	3,767,773 +969,057	+35%	+$11.5M	0.48%	27
2024 Q3	$32.3M	Hold	2,798,716	–	–	0.33%	33
2024 Q2	$29.6M	Sell	2,798,716 -4,615,118	-62%	-$50.6M	0.38%	34
2024 Q1	$78.1M	Sell	7,413,834 -179,190	-2%	-$1.93M	0.98%	13
2023 Q4	$85.3M	Sell	7,593,024 -4,284,147	-36%	-$41.8M	0.97%	12
2023 Q3	$139M	Buy	11,877,171 +2,448,579	+26%	+$27.7M	0.8%	8
2023 Q2	$95M	Buy	9,428,592 +4,651,162	+97%	+$41.6M	0.55%	16
2023 Q1	$35.3M	Buy	4,777,430 +4,060,777	+567%	+$33.4M	0.19%	27
2022 Q4	$5.73M	Buy	+716,653	New	+$3.99M	0.03%	76

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Baker Bros. Advisors's ROIV Position: Q2 2026 in Review

Baker Bros. Advisors reduced its Roivant Sciences (ROIV) stake by 3.1% in Q2 2026, selling an estimated $4.46M and leaving 4,716,831 shares worth $167M. The position accounts for 0.84% of the portfolio, ranked #19.

Baker Bros. Advisors first reported a position in ROIV in Q4 2022 and has held it in 15 quarters since. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Baker Bros. Advisors held 4,716,831 shares of Roivant Sciences worth $167M as of Q2 2026.
Baker Bros. Advisors sold 150,892 Roivant Sciences shares in Q2 2026, an estimated $4.46M.
Roivant Sciences made up 0.84% of Baker Bros. Advisors's portfolio in Q2 2026, its #19 holding.
Baker Bros. Advisors first reported a position in Roivant Sciences in Q4 2022 and has held it in 15 quarters since.
499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.